GSK GlaxoSmithKline PLC ADR

$40.19

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About GlaxoSmithKline PLC ADR

GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.

Website: https://www.gsk.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1131399
Address
980 GREAT WEST ROAD, BRENTFORD MIDDLESEX, GB
Valuation
Market Cap
$72.79B
P/E Ratio
21.78
PEG Ratio
0.35
Price to Book
4.03
Performance
EPS
$1.65
Dividend Yield
4.33%
Profit Margin
8.21%
ROE
22.80%
Technicals
50D MA
$37.51
200D MA
$37.73
52W High
$44.37
52W Low
$31.37
Fundamentals
Shares Outstanding
2B
Target Price
$42.87
Beta
0.30

GSK EPS Estimates vs Actual

● Estimated
● Actual

GSK News & Sentiment

Aug 21, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of GSK plc - GSK - GSK ( NYSE:GSK )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ( "GSK" or the "Company" ) GSK. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Aug 21, 2025 • Benzinga NEUTRAL
Why Is Gilead Sciences Stock Falling Thursday? - CVS Health ( NYSE:CVS ) , Gilead Sciences ( NASDAQ:GILD )
CVS rejects Gilead's $28K-a-year HIV prevention drug Yeztugo from coverage. The federal judge ordered CVS Caremark to pay nearly $290 million in Medicare fraud cases. Get more market-moving news first with AI-powered analysis that turns noise into opportunity. CVS Health Inc.
Aug 18, 2025 • Zacks Commentary SOMEWHAT-BULLISH
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?
Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.
Aug 17, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK - GSK ( NYSE:GSK )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ( "GSK" or the "Company" ) GSK. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Aug 13, 2025 • Zacks Commentary NEUTRAL
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
Aug 11, 2025 • Benzinga NEUTRAL
Global Cancer Vaccines Market to Surpass USD 15.00 Billion by 2032, Unlocking Over USD 10 Billion in New Growth Opportunities | MarketsandMarkets™.
Delray Beach, FL, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- The global cancer vaccines market is on track to nearly double over the next decade, climbing from USD 9.84 billion in 2024 to USD 15.00 billion by 2032 at a CAGR of 5.4%, according to MarketsandMarkets™.
Sentiment Snapshot

Average Sentiment Score:

0.127
50 articles with scored sentiment

Overall Sentiment:

Neutral

GSK Reported Earnings

Feb 05, 2025
Dec 31, 2024 (Pre market)
0.09 Surprise
  • Reported EPS: $0.58
  • Estimate: $0.49
  • Whisper: —
  • Surprise %: 18.8%
Oct 30, 2024
Sep 30, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $1.29
  • Estimate: $1.23
  • Whisper: —
  • Surprise %: 4.9%
Jul 31, 2024
Jun 30, 2024 (Pre market)
0.11 Surprise
  • Reported EPS: $1.10
  • Estimate: $0.99
  • Whisper: —
  • Surprise %: 11.1%
May 01, 2024
Mar 31, 2024 (Pre market)
0.18 Surprise
  • Reported EPS: $1.09
  • Estimate: $0.91
  • Whisper: —
  • Surprise %: 19.8%
Jan 31, 2024
Dec 31, 2023 (Pre market)
-0.04 Surprise
  • Reported EPS: $0.72
  • Estimate: $0.76
  • Whisper: —
  • Surprise %: -5.3%
Nov 01, 2023
Sep 30, 2023 (Pre market)
0.14 Surprise
  • Reported EPS: $1.28
  • Estimate: $1.14
  • Whisper: —
  • Surprise %: 12.3%
Jul 26, 2023
Jun 30, 2023 (Pre market)
0.1 Surprise
  • Reported EPS: $0.97
  • Estimate: $0.87
  • Whisper: —
  • Surprise %: 11.5%
Apr 26, 2023
Mar 31, 2023 (Pre market)
0.08 Surprise
  • Reported EPS: $0.90
  • Estimate: $0.82
  • Whisper: —
  • Surprise %: 9.8%
Feb 01, 2023
Dec 31, 2022 (Pre market)
0.11 Surprise
  • Reported EPS: $0.61
  • Estimate: $0.50
  • Whisper: —
  • Surprise %: 22.0%

Financials